CLINICAL STUDIES
Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction
A meta-analysis of randomized clinical trials
Michael J. Domanski, MD, FACCa,
Derek V. Exner, MDa,1,
Craig B. Borkowf, PhD ,
Nancy L. Geller, PhD,
Yves Rosenberg, MD, MPHa and
Marc A. Pfeffer, MD, PhD, FACC#
a Clinical Trials Group, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
Office of Biostatistics Research, National Heart, Lung and Blood Institute, Bethesda, Maryland, USA
# Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Manuscript received February 18, 1998;
revised manuscript received October 22, 1998,
accepted November 16, 1998.
Reprint requests and correspondence: Michael J. Domanski, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892
Domanskm{at}gwgate.nhlbi.nih.gov
OBJECTIVES
Estimate the effect of angiotensin converting enzyme (ACE) inhibitors on the risk of sudden cardiac death (SCD) following myocardial infarction (MI).
BACKGROUND
Trials in post-MI patients have shown that ACE inhibitor therapy reduces mortality. However, the effect on SCD as a mechanism has not been clarified.
METHODS
Trials of ACE inhibitor therapy following MI reported between January, 1978 and August, 1997 were identified. Studies were included if they met the following criteria: 1) randomized comparison of ACE inhibitor to placebo within 14 days of MI; 2) study duration/blinded follow-up of  6 weeks; 3) the number of deaths and modes of death were reported or could be obtained from the investigators.
RESULTS
We identified 374 candidate articles, of which 15 met the inclusion criteria. The 15 trials included 15,104 patients, 2,356 of whom died. Most (87%) fatalities were cardiovascular and 900 were SCDs. A significant reduction in SCD risk or a trend towards this was observed in all of the larger (N > 500) trials. Overall, ACE inhibitor therapy resulted in significant reductions in risk of death (random effects odds ratio [OR] = 0.83; 95% confidence interval [CI] 0.71–0.97), cardiovascular death (OR = 0.82; 95% CI 0.69–0.97) and SCD (OR = 0.80; 95% CI 0.70–0.92).
CONCLUSIONS
This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality. Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | AAD | = antiarrhythmic drug | | CI | = confidence interval | | MI | = myocardial infarction | | OR | = odds ratio | | SCD | = sudden cardiac death |
|
This article has been cited by other articles:
|
|
|
|
 
M. L. Kukin, R. Kapoor, J. R. Kapoor, and R. J. Myerburg
Implantable Cardioverter-Defibrillators
N. Engl. J. Med.,
February 26, 2009;
360(9):
937 - 938.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Due-Andersen, T. Hoi-Hansen, C. E. Larroude, N. V. Olsen, J. K. Kanters, F. Boomsma, U. Pedersen-Bjergaard, and B. Thorsteinsson
Cardiac repolarization during hypoglycaemia in type 1 diabetes: impact of basal renin-angiotensin system activity
Europace,
July 1, 2008;
10(7):
860 - 867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Due-Andersen, T. Hoi-Hansen, N. V. Olsen, C. E. Larroude, J. K. Kanters, F. Boomsma, U. Pedersen-Bjergaard, and B. Thorsteinsson
Cardiac repolarization during hypoglycaemia and hypoxaemia in healthy males: impact of renin-angiotensin system activity
Europace,
February 1, 2008;
10(2):
219 - 226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Myles, C. E. Jackson, I. Tsorlalis, M. C. Petrie, J. J. V. McMurray, and S. M. Cobbe
Is Microvolt T-Wave Alternans the Answer to Risk Stratification in Heart Failure?
Circulation,
December 18, 2007;
116(25):
2984 - 2991.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. S. Kasi, H. D. Xiao, L. L. Shang, S. Iravanian, J. Langberg, E. A. Witham, Z. Jiao, C. J. Gallego, K. E. Bernstein, and S. C. Dudley Jr.
Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation
Am J Physiol Heart Circ Physiol,
July 1, 2007;
293(1):
H182 - H192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Kloner and D. S. Cannom
Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices
Circulation,
June 12, 2007;
115(23):
2983 - 2989.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. H. Pun, R. W. Lehrich, S. R. Smith, and J. P. Middleton
Predictors of Survival after Cardiac Arrest in Outpatient Hemodialysis Clinics
Clin. J. Am. Soc. Nephrol.,
May 1, 2007;
2(3):
491 - 500.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Rosen, D. M. Cutler, D. M. Norton, H. M. Hu, and S. Vijan
The Value Of Coronary Heart Disease Care For The Elderly: 1987-2002
Health Aff.,
January 1, 2007;
26(1):
111 - 123.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sanders, J. Harris, J. Cooper, P. Gohlke, S. E Humphries, H. Montgomery, and D. R Woods
Lack of change in serum angiotensin-converting enzyme activity during the menstrual cycle
Journal of Renin-Angiotensin-Aldosterone System,
December 1, 2006;
7(4):
231 - 235.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Kirchhof, G. Breithardt, and L. Eckardt
Primary prevention of sudden cardiac death
Heart,
December 1, 2006;
92(12):
1873 - 1878.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Abdulla, L. Kober, E. Christensen, and C. Torp-Pedersen
Effect of beta-blocker therapy on functional status in patients with heart failure -- A meta-analysis
Eur J Heart Fail,
August 1, 2006;
8(5):
522 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I Gemmell, R F Heller, P McElduff, K Payne, G Butler, R Edwards, M Roland, and P Durrington
Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease
J Epidemiol Community Health,
December 1, 2005;
59(12):
1041 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pitt, the EPHESUS Investigators, F. Zijlstra, I. C.C. van der Horst, A. Khera, B. D. Levine, A. G. Jacobs, S. D. Solomon, R. M. Califf, M. A. Pfeffer, et al.
Sudden Death in Patients with Myocardial Infarction
N. Engl. J. Med.,
September 22, 2005;
353(12):
1294 - 1297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Macchia, G. Levantesi, M. G. Franzosi, E. Geraci, A. P. Maggioni, R. Marfisi, G. L. Nicolosi, C. Schweiger, L. Tavazzi, G. Tognoni, et al.
Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids
Eur J Heart Fail,
August 1, 2005;
7(5):
904 - 909.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raviele, M. G. Bongiorni, M. Brignole, R. Cappato, A. Capucci, F. Gaita, M. Gulizia, S. Mangiameli, A. S. Montenero, R. F. E. Pedretti, et al.
Early EPS/ICD strategy in survivors of acute myocardial infarction with severe left ventricular dysfunction on optimal beta-blocker treatment: The BEta-blocker STrategy plus ICD trial
Europace,
January 1, 2005;
7(4):
327 - 337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. D. Solomon, D. Wang, P. Finn, H. Skali, L. Zornoff, J. J.V. McMurray, K. Swedberg, S. Yusuf, C. B. Granger, E. L. Michelson, et al.
Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) Program
Circulation,
October 12, 2004;
110(15):
2180 - 2183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Teo, L. B. Mitchell, J. Pogue, J. Bosch, G. Dagenais, S. Yusuf, and on behalf of the HOPE Investigators
Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction
Circulation,
September 14, 2004;
110(11):
1413 - 1417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Josephson and H. J.J. Wellens
Implantable Defibrillators and Sudden Cardiac Death
Circulation,
June 8, 2004;
109(22):
2685 - 2691.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. St John Sutton, D. Lee, J. L. Rouleau, S. Goldman, T. Plappert, E. Braunwald, and M. A. Pfeffer
Left Ventricular Remodeling and Ventricular Arrhythmias After Myocardial Infarction
Circulation,
May 27, 2003;
107(20):
2577 - 2582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Kennedy and R. S. Rosenson
Physicians' interpretation of "class effects": A need for thoughtful re-evaluation
J. Am. Coll. Cardiol.,
July 3, 2002;
40(1):
19 - 26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gandjour, F. Kleinschmit, K.W. Lauterbach, and INTERCARE Iternational Investigators
European comparison of costs and quality in the treatment of acute myocardial infarction (2000-2001)
Eur. Heart J.,
June 1, 2002;
23(11):
858 - 868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Allot, C de Chillou, and N Sadoul
Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials
Eur. Heart J. Suppl.,
April 1, 2002;
4(suppl_D):
D31 - D42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Schneeweiss, S. B. Soumerai, R. J. Glynn, M. Maclure, C. Dormuth, and A. M. Walker
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
Can. Med. Assoc. J.,
March 1, 2002;
166(6):
737 - 745.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. de Lorgeril, P. Salen, P. Defaye, P. Mabo, and F. Paillard
Dietary prevention of sudden cardiac death
Eur. Heart J.,
February 2, 2002;
23(4):
277 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, J. A. Camm, R. Cappato, S. M. Cobbe, C. Di Mario, et al.
TASK FORCE ON SUDDEN CARDIAC DEATH, EUROPEAN SOCIETY OF CARDIOLOGY: Summary of Recommendations
Europace,
January 1, 2002;
4(1):
3 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. M. Curtis and J. H. O'Keefe Jr
Autonomic Tone as a Cardiovascular Risk Factor: The Dangers of Chronic Fight or Flight
Mayo Clin. Proc.,
January 1, 2002;
77(1):
45 - 54.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A H Gershlick
The acute management of myocardial infarction
Br. Med. Bull.,
October 1, 2001;
59(1):
89 - 112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J.,
August 2, 2001;
22(16):
1374 - 1450.
[PDF]
|
|
|
|
|
|
|
M. E. Khalil, A. W. Basher, E. J. Brown Jr, and I. A. Alhaddad
A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients
J. Am. Coll. Cardiol.,
June 1, 2001;
37(7):
1757 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Mazeika
Aborted sudden cardiac death: a clinical perspective
Postgrad. Med. J.,
June 1, 2001;
77(908):
363 - 370.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Babuty and M. J Lab
Mechanoelectric contributions to sudden cardiac death
Cardiovasc Res,
May 1, 2001;
50(2):
270 - 279.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.R. Woods, D. Brull, and H. Montgomery
Increased QT dispersion with the D-allele of the ACE polymorphism
Eur. Heart J.,
April 2, 2001;
22(8):
618 - 621.
[PDF]
|
|
|
|
|
|
|
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme
Eur. Heart J.,
April 1, 2001;
22(7):
554 - 572.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Galcera-Tomas, F. J. Castillo-Soria, M. Villegas-Garcia, R. Florenciano-Sanchez, J. G. Sanchez-Villanueva, J. A. N. de la Rosa, A. Martinez-Caballero, J. A. Valenti-Aldeguer, P. Jara-Perez, M. Parraga-Ramirez, et al.
Effects of Early Use of Atenolol or Captopril on Infarct Size and Ventricular Volume : A Double-Blind Comparison in Patients With Anterior Acute Myocardial Infarction
Circulation,
February 13, 2001;
103(6):
813 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie
Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
J. Am. Coll. Cardiol.,
January 1, 2001;
37(1):
1 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E WIEGERS and M. S. J. SUTTON
When should ACE inhibitors or warfarin be discontinued after myocardial infarction?
Heart,
October 1, 2000;
84(4):
361 - 362.
[Full Text]
|
|
|
|
|
|
|
S. Saksena
Implantable defibrillators in the third millennium: increasingly relegated to a standby role?
J. Am. Coll. Cardiol.,
September 1, 2000;
36(3):
828 - 831.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E.E. van der Wall and J.J. Bax
Different imaging approaches in the assessment of left ventricular dysfunction: all things equal?
Eur. Heart J.,
August 2, 2000;
21(16):
1295 - 1297.
[PDF]
|
|
|
|
|
|
|
S. Greenberg, G. Chemin, I. Shapira, J. George, Y. Wollman, S. Laniado, and G. Keren
Captopril and L-Arginine Have a Synergistic Cardioprotective Effect in Ischemic-Reperfusion Injury in the Isolated Rat Heart
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 2000;
5(4):
281 - 290.
[Abstract]
[PDF]
|
|
|
|
|
|
|
ACE Inhibitors Reduce Sudden Cardiac Death
Journal Watch Cardiology,
May 7, 1999;
1999(507):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
ACE Inhibitors Reduce Sudden Cardiac Death After MI
Journal Watch Dermatology,
May 1, 1999;
1999(501):
18 - 18.
[Full Text]
|
|
|
|
|
|
|
ACE Inhibitors Reduce Sudden Cardiac Death After MI
Journal Watch (General),
March 16, 1999;
1999(316):
2 - 2.
[Full Text]
|
|
|
|
